Herbs & Botanicals · Very bitter Ayurvedic herb
Chirata
Swertia chirayita · also called Chirata, chiretta, chirayita, chiraito, Indian gentian, bitter stick
Chirata is a very bitter Himalayan plant used in Ayurveda for fever, digestion, jaundice and diabetes. We found no trial in people, only traditional use and studies in animals and cells, so every use is rated insufficient. The key cautions are low blood sugar if you take diabetes medicines, no safety data in pregnancy, and wild plants that are endangered and often substituted.
General information, not medical advice. Last substantive update · Not medically reviewed. A named clinician has not signed off on this page. How this page is made
About Chirata
Chirata is a bitter Himalayan herb long used in Ayurveda for fever and digestion. Research is mostly in animals and cells, so we cannot say if it works in people. Take care with diabetes medicines, in pregnancy, and when buying it, as the wild plant is endangered and can be substituted.
What it is
Chirata is Swertia chirayita, a plant of the gentian family that grows in the temperate Himalayas. The whole plant, including the roots, is dried and used.
Its taste is very bitter, thanks to compounds such as amarogentin and swertiamarin. It is related to gentian and centaury, two European bitter herbs.
What the evidence shows
We found no controlled trial of chirata in people. What exists is traditional use, reviews, animal studies and test-tube work.
Pure amarogentin lowered blood sugar in diabetic rats, and a chirata extract protected mouse livers from paracetamol injury. Reviews of the plant and of the wider gentian family agree that clinical trials are still needed.
Quality, adulteration and the endangered wild plant
Wild chirata has declined across the Himalayas, and reviews call it endangered. India has restricted export of wild-harvested chirata since 2004. Cultivation in Nepal now supplies much of the trade.
A lab study showed that other Swertia species and Halenia elliptica can be told apart from chirata by chemical fingerprint, which suggests they may be used as substitutes. Look for the Latin name, the plant part and a cultivated source.
At a glance
Traditional uses history, not proof
- Fever and malaria-like illnesses
- Appetite and digestion (bitter tonic)
- Jaundice and liver complaints
- Diabetes
- Skin problems and worms
Studied for research
- Blood sugar and diabetes: insufficient (animals only)
- Liver protection: insufficient (mice and cells only)
- Digestion, appetite and fever: insufficient (traditional use)
- Inflammation and antioxidant activity: insufficient (animals and cells)
- Infections including malaria: insufficient (test tube only)
Main compounds
- Amarogentin
- Swertiamarin
- Mangiferin
Common forms
- Dried whole plant or powder
- Capsules or tablets
- Extract
- Tincture or infusion
- Ayurvedic multi-herb formulas
Research links: PubMed: chirata comprehensive review (2023) · PubMed: chirata traditional medicinal plant review (2016) · PubMed: chirata trade and conservation (2018) · PubMed: chirata and diabetes review (2020) · Research Library · Genes & Biomarkers Library
The plant and its history
- Accepted scientific name
- Swertia chirayita (Roxb.) H.Karst.
- Naming authority
- GBIF species match read 2026-10-25: ACCEPTED, key 7419749, family Gentianaceae, confidence 99. GBIF also lists Swertia chirata C.B.Clarke as a separate ACCEPTED name (key 5596317).
- Synonyms
- Swertia chirata C.B.Clarke; Swertia chirata Buch.-Ham. ex Wall.; Swertia chirayita (Roxb.) Buch.-Ham.; Swertia chirayita (Roxb. ex Fleming) Buch.-Ham. ex C.B.Clarke
- Common names
- Chirata (English); Chiretta (English); Chirayita (Ayurvedic name); Chiraito (Nepali); Indian gentian (English); Bitter stick (English)
- Botanical family
- Gentianaceae
- Classification
- Plantae > Gentianaceae > Swertia > Swertia chirayita
- Native range
- Temperate Himalaya, from Kashmir to Bhutan, at roughly 1200-2100 m altitude, in moist shady places (per Kumar and Van Staden 2016).
- Habitat
- High-altitude Himalayan slopes (per the same review).
- What the plant looks like
- Roots: Underground parts are used medicinally.; Stems: Not covered.; Leaves: Not covered.; Flowers: Not covered.; Fruit: Not covered.
- Cultivation
- Cultivated in eastern Nepal for about 25 years; cultivation is described as profitable but prices fell between 2013 and 2017 (Cunningham 2018).
- Harvest and processing
- Traded as dried whole plant or whole-plant extract.
- Look-alikes and adulterants
- Name: Other Swertia species and Halenia elliptica; Note: Possible substitutes; a chemical fingerprint can tell them from chirata (Singh 2019).; Name: Kalmegh (Andrographis paniculata); Note: A different plant, also very bitter, sometimes treated as an alternative in traditional use.; Name: Gentian and centaury; Note: Related bitter herbs, not the same plant.
- Sustainability and conservation
- A 2016 review calls it critically endangered (citing an IUCN-criteria assessment from 2005); this was not checked on the Red List. India has restricted export of wild-harvested material since 2004.
Traditional use and history history, not clinical proof
| Tradition or era | Documented use | Source |
|---|---|---|
| Ayurveda, Unani, Siddha and other traditional systems | Used for fever, vomiting, jaundice, digestive disorders, diabetes, malaria and skin diseases; listed in Indian, British and American pharmacopoeias. | p26793105 |
| Tibetan medicine | Used as a bitter herb in Tibetan practice; trade goes to Tibet as well as India. | p29960022 |
| Modern trade | One of Nepal's top-earning medicinal plant exports (per a 2018 trade review). | p29960022 |
Traditional use shows how a plant was used. It does not show that a supplement works or is safe today.
What is inside, and how it may work
What the plant contains and how those compounds act in cells and animals. Laboratory and animal mechanisms are not proven effects in people.
Main compounds
| Compound | Family | Where it is concentrated | Activity studied | Level of evidence |
|---|---|---|---|---|
| Amarogentin PubChem 115149 | secoiridoid glycoside | Whole plant | One of the most bitter compounds known; lowered blood glucose in diabetic rats in one study. 10 12 | Animal research |
| Swertiamarin PubChem 442435 | secoiridoid glycoside | Whole plant | Studied for antidiabetic, anti-inflammatory and antioxidant effects, mostly from Enicostemma plants, in lab and animal work. 10 8 13 | Animal research |
| Mangiferin PubChem 5281647 | xanthone C-glycoside | Whole plant | A marker compound measured to check authenticity; effects are mostly lab and animal. 10 13 | Laboratory research |
Mechanisms, receptors and pathways
| Target or pathway | Gene or receptor | What was found | Level |
|---|---|---|---|
| Glucose handling (GLUT4, PEPCK) | GLUT4 (SLC2A4), PEPCK (PCK1) | Pure amarogentin raised muscle GLUT4 and lowered liver PEPCK in diabetic rats. 12 | Animal research |
| Oxidative stress in liver | Not read beyond abstract | Extract lowered liver damage markers in paracetamol-injured mice. 11 | Animal research |
| Hepatitis B virus markers | Not applicable | Compounds lowered HBsAg, HBeAg and viral DNA copying in infected liver cells. 15 | Lab |
Absorption, metabolism and elimination
- Absorption
- No human data. Not covered in abstracts we read.
- Distribution
- Not covered.
- Metabolism
- Not covered.
- Elimination
- Not covered.
- Bioavailability
- Not studied in people for chirata. Our earlier summary says swertiamarin is poorly absorbed by mouth in rats; that source was not re-read.
Isolated compounds versus whole extracts
Most mechanism work uses single compounds (amarogentin, swertiamarin, mangiferin). Results with a pure compound do not tell us how a whole-plant product behaves, and extracts differ from product to product.
Nutritional composition
Chirata is a medicinal bitter herb, not a food or nutrient.
6 not enough evidence
What is Chirata good for?
These are the uses people ask about. For each one the honest rating is shown. Every rating here is insufficient, because no study in people was found.
Benefits, one by one
Each card is a research question, not a promise. Tap a goal to filter. Open a card to see the studies, doses and limits.
Blood sugar and diabetes (traditional use; animal and lab work only)
Not enough evidenceChirata is used in Ayurveda as a bitter herb for diabetes, and rat studies of chirata extracts and of one of its bitter compounds, amarogentin, show lower blood sugar. We found no trial in people, so we cannot say whether it lowers blood sugar in humans or how safely.
5 studiesNo amount or form is recommended here. Ask a doctor or pharmacist abo…
Studies, doses and limits
What the trials found
No controlled trial in people was found in the reviews or searches. A 2020 review says the compounds have not been well characterised for human use and that safety work is needed. A 2025 review of the whole gentian family says well-designed clinical trials are still needed.
Results
Animals: blood sugar fell in diabetic rats given pure amarogentin. People: no data. Numbers from reviews were not read beyond abstracts.
Effect sizes as reported
None.
Why this rating
Animal and lab findings only, no human trial. Reviews are narrative and cite mixed-quality studies.
Form and dose studied
No amount or form is recommended here. Ask a doctor or pharmacist about amounts.
Who was studied
Adults with diabetes use chirata traditionally; no study in this group.
Limits
Abstracts only. The animal study used a pure compound, not chirata. Gentian-family reviews are not chirata-specific.
Why researchers looked
Diabetes is a common long-term condition, and bitter plants are an old folk remedy for it. Reviews list chirata as one of the plants with blood-sugar-lowering potential.
Traditional use
Ayurvedic and other South Asian traditions use chirata for diabetes, often as part of mixed herbal formulas.
Proposed mechanism Animal research
In rats, the isolated compound amarogentin raised the muscle sugar-transporter GLUT4 and lowered a liver enzyme (PEPCK) that makes sugar. This has not been shown to explain any effect in people.
A proposed mechanism does not show that the effect happens in people.
Do not replace diabetes medicines or monitoring. If you take insulin or tablets for diabetes, chirata could in theory add to the blood-sugar drop (see Safety); this is not confirmed in people.
Liver protection (mouse and cell studies only)
Not enough evidenceIn mice given paracetamol to injure the liver, a chirata extract lowered the liver blood tests and kept the tissue healthier. Compounds from chirata also lowered hepatitis B markers in infected cells in the lab. Nothing has been tested in people, so chirata cannot be called a liver treatment.
4 studiesNo amount or form is recommended here. Ask a doctor or pharmacist abo…
Studies, doses and limits
What the trials found
No human data found. Mouse study (Nagalekshmi 2011): extract at 100-200 mg/kg protected against paracetamol injury, dose-dependently. Cell study (Zhou 2015): several chirata compounds lowered hepatitis B antigen release and viral DNA copying in a liver cell line.
Results
Mice: significantly lower liver enzymes and less tissue damage. Cells: some compounds reduced hepatitis B markers. People: none.
Effect sizes as reported
None.
Why this rating
Animal and cell work only; no human trial of any kind.
Form and dose studied
No amount or form is recommended here. Ask a doctor or pharmacist about amounts.
Who was studied
Laboratory mice and a human liver cell line.
Limits
Abstracts only. The mouse model is a one-off acute injury. The reviews are narrative.
Why researchers looked
Chirata is used in Ayurveda and Tibetan medicine for jaundice and liver complaints, so scientists test it on injured animal livers and virus-infected liver cells.
Traditional use
Traditional use for jaundice and liver disorders in India, Nepal and Tibet.
Proposed mechanism Animal research
Lab work suggests antioxidant effects and lower oxidative damage markers in the liver. Not shown in people.
A proposed mechanism does not show that the effect happens in people.
Protection in a mouse does not mean safety for a person with liver disease. Yellow skin or eyes, dark urine or severe tiredness need medical care. See the Safety tab on the lack of human liver safety data.
Digestion, appetite, fever and worms (traditional use only)
Not enough evidenceChirata is a very bitter plant, and bitter plants have long been used to stir appetite and settle digestion. Traditional systems also use it for fever, vomiting and worms. We found no trial testing any of these uses in people.
2 studiesNo amount or form is recommended here. Ask a doctor or pharmacist abo…
Studies, doses and limits
What the trials found
None found. Two reviews describe the traditional uses; neither reports a human trial of chirata for digestion or fever.
Results
No results in people.
Effect sizes as reported
None.
Why this rating
Traditional use only; reviews do not cite controlled human studies for these uses.
Form and dose studied
No amount or form is recommended here. Ask a doctor or pharmacist about amounts.
Who was studied
Adults in traditional practice
Limits
Abstracts and a partial full text; no trial data.
Why researchers looked
This is what chirata is best known for in practice: a bitter tonic taken before or after meals in traditional systems.
Traditional use
Ayurveda, Unani and Siddha medicine use chirata for fever, vomiting, digestive problems and jaundice, and the plant has been listed in Indian, British and American pharmacopoeias.
Proposed mechanism Pharmacological theory
Bitter taste is thought to prompt digestive juices through taste receptors; this is a general idea about bitter herbs and has not been tested for chirata.
A proposed mechanism does not show that the effect happens in people.
Bitter herbs can irritate the stomach in some people; ask a doctor if you have an ulcer or reflux. Fever that lasts needs medical care.
Inflammation, pain and antioxidant activity (animal and lab only)
Not enough evidenceChirata extracts and compounds reduce inflammation and oxidative stress markers in animals and cells. No human study has tested whether this helps pain or swelling in people.
3 studiesNo amount or form is recommended here. Ask a doctor or pharmacist abo…
Studies, doses and limits
What the trials found
No human data found. Reviews list anti-inflammatory and antioxidant findings from lab and animal studies; a 2025 gentian-family review says the same for the family as a whole.
Results
No human results.
Effect sizes as reported
None.
Why this rating
Animal and cell findings only.
Form and dose studied
No amount or form is recommended here. Ask a doctor or pharmacist about amounts.
Who was studied
Cells and laboratory animals.
Limits
Abstracts only; the family review is not chirata-specific.
Why researchers looked
Reviews of the plant list anti-inflammatory and antioxidant effects as among its main lab findings.
Traditional use
Used traditionally for fever, skin problems and general inflammation in Ayurveda.
Proposed mechanism Animal research
Lab work reports antioxidant activity and effects on inflammation signals. Results are from cells and animals.
A proposed mechanism does not show that the effect happens in people.
Not shown to relieve pain or swelling in people; do not delay care for ongoing pain.
Infections, malaria and antiviral activity (test-tube work only)
Not enough evidenceIn the lab, extracts and compounds from chirata have shown activity against some germs, the malaria parasite and a hepatitis B virus model. No human has been shown to be treated successfully, and malaria needs proper medical treatment.
3 studiesNo amount or form is recommended here. Ask a doctor or pharmacist abo…
Studies, doses and limits
What the trials found
No human trial found. A 2001 lab study tested chirata extracts against malaria parasites in the test tube (its abstract gives no numbers). A 2015 cell study found some compounds lowered hepatitis B markers.
Results
No results in people.
Effect sizes as reported
None.
Why this rating
Test-tube evidence only.
Form and dose studied
No amount or form is recommended here. Ask a doctor or pharmacist about amounts.
Who was studied
Parasites and virus-infected cells in the lab.
Limits
Abstracts only; the malaria abstract does not give results.
Why researchers looked
Chirata has been used in folk medicine for fever and malaria, so it was tested against the malaria parasite and other germs in the lab.
Traditional use
Used in Ayurveda and folk medicine for fevers and malaria-like illnesses.
Proposed mechanism Laboratory research
Not established. Lab tests show activity in cells, which is far from a working treatment.
A proposed mechanism does not show that the effect happens in people.
Malaria and other fevers can be fatal and need medical care and tested medicines. Chirata is not a substitute for them.
Cancer cells in the lab (test-tube work only)
Not enough evidenceReviews list antitumor findings for chirata extracts and compounds in cell tests. No study in people was found, and cell tests are not evidence that an herb treats cancer.
1 studiesNo amount or form is recommended here. Ask a doctor or pharmacist abo…
Studies, doses and limits
What the trials found
None found in people. One review abstract lists antitumor activity among the lab findings.
Results
No human results.
Effect sizes as reported
None.
Why this rating
Lab cell findings only.
Form and dose studied
No amount or form is recommended here. Ask a doctor or pharmacist about amounts.
Who was studied
Cancer cell lines.
Limits
Abstract only.
Why researchers looked
Bitter compounds such as amarogentin are tested for effects on cancer cells in the lab.
Traditional use
Not a traditional use in the sources we read.
Proposed mechanism Laboratory research
Cell-level effects only; not shown in people.
A proposed mechanism does not show that the effect happens in people.
Do not use chirata in place of cancer treatment.
Connections to the rest of health
How Chirata connects to the rest of our health knowledge graph. Every link says what kind of connection it is. A safety link (for example to the liver) is a warning, not a benefit. A study that merely mentions a topic never creates a benefit link.
Explore every connection: goals, body systems, organs, symptoms, genes
A. Wellness goals
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Blood Sugar Balance | Traditional use | Not enough evidence | Blood sugar and diabetes (traditional use; animal and lab work only): Chirata is used in Ayurveda as a bitter herb for diabetes, and rat studies of chirata extracts and of one of its bitter compounds, amarogentin, show lower blood sugar. We found no trial in people, so we cannot say whether it lowers blood sugar in humans or how safely. | 4 5 12 7 8 |
| Metabolic Health | Traditional use | Not enough evidence | Blood sugar and diabetes (traditional use; animal and lab work only): Chirata is used in Ayurveda as a bitter herb for diabetes, and rat studies of chirata extracts and of one of its bitter compounds, amarogentin, show lower blood sugar. We found no trial in people, so we cannot say whether it lowers blood sugar in humans or how safely. | 4 5 12 7 8 |
| Liver Support | Not enough evidence | Liver protection (mouse and cell studies only): In mice given paracetamol to injure the liver, a chirata extract lowered the liver blood tests and kept the tissue healthier. Compounds from chirata also lowered hepatitis B markers in infected cells in the lab. Nothing has been tested in people, so chirata cannot be called a liver treatment. | 11 15 7 14 | |
| Digestive Support | Traditional use | Not enough evidence | Digestion, appetite, fever and worms (traditional use only): Chirata is a very bitter plant, and bitter plants have long been used to stir appetite and settle digestion. Traditional systems also use it for fever, vomiting and worms. We found no trial testing any of these uses in people. | 7 14 |
| Gut Health | Traditional use | Not enough evidence | Digestion, appetite, fever and worms (traditional use only): Chirata is a very bitter plant, and bitter plants have long been used to stir appetite and settle digestion. Traditional systems also use it for fever, vomiting and worms. We found no trial testing any of these uses in people. | 7 14 |
| Inflammation Balance | Not enough evidence | Inflammation, pain and antioxidant activity (animal and lab only): Chirata extracts and compounds reduce inflammation and oxidative stress markers in animals and cells. No human study has tested whether this helps pain or swelling in people. | 14 7 1 | |
| Cellular Protection | Not enough evidence | Inflammation, pain and antioxidant activity (animal and lab only): Chirata extracts and compounds reduce inflammation and oxidative stress markers in animals and cells. No human study has tested whether this helps pain or swelling in people. Cancer cells in the lab (test-tube work only): Reviews list antitumor findings for chirata extracts and compounds in cell tests. No study in people was found, and cell tests are not evidence that an herb treats cancer. | 14 7 1 | |
| Immune Support | Not enough evidence | Infections, malaria and antiviral activity (test-tube work only): In the lab, extracts and compounds from chirata have shown activity against some germs, the malaria parasite and a hepatitis B virus model. No human has been shown to be treated successfully, and malaria needs proper medical treatment. | 2 15 14 |
B. Body systems
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Endocrine System | Biological association | Not enough evidence | Studied for: Blood sugar and diabetes (traditional use; animal and lab work only) | 4 5 12 7 8 |
| Hepatic System | Biological association | Not enough evidence | Studied for: Liver protection (mouse and cell studies only) | 11 15 7 14 |
| Digestive System | Biological association | Not enough evidence | Studied for: Digestion, appetite, fever and worms (traditional use only) | 7 14 |
| Immune System | Biological association | Not enough evidence | Studied for: Inflammation, pain and antioxidant activity (animal and lab only) Studied for: Infections, malaria and antiviral activity (test-tube work only) | 14 7 1 2 15 |
L. Active compounds
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Amarogentin | Biological association | Animal | One of the most bitter compounds known; lowered blood glucose in diabetic rats in one study. Preparation or compound: Whole plant |
10 12 |
| Swertiamarin | Biological association | Animal | Studied for antidiabetic, anti-inflammatory and antioxidant effects, mostly from Enicostemma plants, in lab and animal work. Preparation or compound: Whole plant |
10 8 13 |
| Mangiferin | Biological association | In vitro | A marker compound measured to check authenticity; effects are mostly lab and animal. Preparation or compound: Whole plant |
10 13 |
Each connection is stored with the ingredient, the connected record, the kind of connection, the evidence status, the supporting studies, the preparation or compound involved, and a review date (last reviewed October 25, 2026).
The evidence
The research centre for Chirata. Every record here was checked against PubMed or the publisher's page; we never list a study we have not verified.
Evidence by outcome
Bars show how many studies we found for each outcome, not how well it works. People are added up across trials only (reviews are not added, to avoid double counting).
How we rate evidence
High certainty
Several well-run trials or reviews agree; further research is unlikely to change the picture much.
Moderate certainty
Good trials point the same way, but some doubt remains.
Low certainty
Small, short or inconsistent trials. The finding could change with better research.
Very low certainty
Very little or very weak human data. Treat as a possibility only.
Mixed findings
Trials or reviews disagree with each other.
Not enough evidence
Not enough human research to say either way.
Evidence against
Good research found no benefit, or found harm.
We take the reviewers' own risk-of-bias and GRADE statements where they exist, and otherwise judge from study size, design, consistency, directness and whether a product matches what is sold. Many publications do not make evidence high. Method note: We read our existing herb summary, then searched PubMed, read the abstract of each PubMed record cited, and checked names in GBIF and PubChem. Items marked summary-only or not verified were not read further.
Study library: every study we checked 15
| Study | Design | People | Product, dose, length | Result |
|---|---|---|---|---|
| Andryszkiewicz 2025 Gentianaceae Family-Derived Bioactive Compounds-Therapeutic Values and Supporting Role in Inflammation and Detoxification. Nutrients · PMID 40871648 · DOI |
Narrative review review-of-mixed |
Review of gentian-family herbs (not only chirata) | Gentianaceae compounds (xanthones, iridoids, flavonoids) roots and aerial parts Not given here Not given here |
Summarises traditional and laboratory findings on gentian-family compounds and concludes they are a promising source of natural agents, while stressing the need for further research and conservation of threatened species. Methods, limits and fundingOutcomes: Skin, gut, liver, joint and diabetes uses; anti-inflammatory and antioxidant properties Limitations: Abstract only. Family-level review; not specific to chirata; mostly lab data. Funding and conflicts: Authors declared no competing or financial interests. Read: abstract |
| Bhat 2001 In vitro antimalarial activity of extracts of three plants used in the traditional medicine of India. Am J Trop Med Hyg · PMID 11693874 · DOI |
In vitro study in-vitro |
Malaria parasite (Plasmodium falciparum FCK 2) grown in blood cells in the lab | Water and solvent extracts of Swertia chirata, papaya and sweet orange specific plant parts (not named in the abstract) Not given here Not given here |
Extracts were tested against the malaria parasite in the lab. The abstract as retrieved gives the methods but not the results. Methods, limits and fundingOutcomes: Parasite growth, checked on blood smears and by [35S]-methionine uptake Limitations: Test-tube work only; the abstract does not give the result numbers, so none are used here. Read: abstract |
| Cunningham 2018 Production from both wild harvest and cultivation: The cross-border Swertia chirayita (Gentianaceae) trade. J Ethnopharmacol · PMID 29960022 · DOI |
Trade and conservation review review-of-single-species |
Trade and population data for chirata in Nepal and India | Chirata (Swertia chirayita) whole plant (dried whole plant or whole-plant extract) whole plant Not given here Not given here |
Estimated Nepal production of about 711 tonnes in 2013 and about 503 tonnes in 2014, most of it exported to India and Tibet. Declines in wild populations are widely noted across its range. India banned export of wild-harvested chirata, its parts and extracts in 2004 (formulations excepted). Cultivation in eastern Nepal has run for about 25 years and supplies significant quantities, but the price paid to farmers fell from NRs750/kg in April 2013 to NRs250/kg in December 2017, making it less profitable for farmers. Methods, limits and fundingOutcomes: Scale of trade, harvest impacts, cultivation as an alternative to wild collection Limitations: Abstract only. Trade figures are estimates built on assumptions about export shares. Funding and conflicts: One author works for Traditional Medicinals, a herbal products company; the abstract does not say how the study was funded. Read: abstract |
| Dey 2020 Utilization of Swertia chirayita Plant Extracts for Management of Diabetes and Associated Disorders: Present Status, Future Prospects and Limitations. Nat Prod Bioprospect · PMID 33118125 · DOI |
Narrative review review-of-single-species |
Review of chirata extracts and diabetes | Chirata (Swertia chirayita) plant extracts whole plant Not given here Not given here |
Calls chirata known for its blood-sugar-lowering potential. States that the compounds have not been well characterised against human application and that more work is needed on mechanisms and on the safety of the plant formulations. Also discusses biotechnology to conserve this endangered plant. Methods, limits and fundingOutcomes: Antidiabetic properties of chirata extracts, safety needs, conservation Limitations: Abstract only. Narrative review. No human trial is described in the abstract. Funding and conflicts: Authors declared no conflict of interest. Read: abstract |
| Dinić 2025 Therapeutic Potential of Gentianaceae Family Plants in the Treatment of Diabetes and Its Complications. Biomedicines · PMID 41301913 · DOI |
Narrative review review-of-mixed |
Review of gentian-family plants (not only chirata) and diabetes | Gentianaceae plant extracts and isolated compounds various Not given here Not given here |
Says numerous in vitro and in vivo (lab and animal) studies show potential to regulate blood glucose, reduce oxidative stress and improve lipid metabolism, and that future research should prioritise well-designed clinical trials to verify safety and efficacy in humans. Methods, limits and fundingOutcomes: Blood sugar, oxidative stress, beta-cell protection, complications Limitations: Abstract only. Covers the whole plant family, so the result is not specific to chirata. No human trial results in the abstract. Funding and conflicts: Authors declared no conflicts of interest. Read: abstract |
| GBIF Secretariat 2026 GBIF species match: Swertia chirayita and Swertia chirata api.gbif.org · Source |
Database record database |
Taxonomic names | Swertia chirayita not applicable Not given here Not given here |
Read 2026-10-25: Swertia chirayita (Roxb.) H.Karst. is ACCEPTED (key 7419749, family Gentianaceae, match confidence 99). GBIF also lists Swertia chirata C.B.Clarke as a separately ACCEPTED name (key 5596317) and several Buch.-Ham. names as synonyms. Most of the literature treats chirayita and chirata as the same plant. Methods, limits and fundingOutcomes: Accepted names and synonyms Limitations: Name check only. Plants of the World Online and NCBI taxonomy were not checked. Read: full-text |
| Kumar 2016 A Review of Swertia chirayita (Gentianaceae) as a Traditional Medicinal Plant. Front Pharmacol · PMID 26793105 · DOI |
Narrative review review-of-single-species |
Literature review of chirata (open access, PMC4709473) | Chirata (Swertia chirayita) whole plant, root, extracts whole plant and underground parts Not given here Not given here |
Names Ayurveda, Unani and Siddha use and lists the plant in Indian, British and American pharmacopoeias. Says overharvesting and habitat loss have brought the plant close to extinction and that supplies are adulterated. Says there is a lack of adequate information on safety. In the full text: extracts did not cause obvious toxic effects in mice (no differences in body weight or temperature); a toxicity-free result is also cited for lab tests of liposome and niosome forms; the authors call for formal toxicity and mutagenicity tests and clinical safety studies. The review calls the plant critically endangered under IUCN criteria, citing a 2005 source. Methods, limits and fundingOutcomes: Traditional use, chemistry, pharmacology, safety, conservation Limitations: Narrative review; most of the evidence in it is lab or animal. Full text read only for the safety, conservation and table sections. The IUCN statement was not checked against the Red List itself. Read: full-text (partial) |
| Leong 2016 A systematic review of the protective role of swertiamarin in cardiac and metabolic diseases. Biomed Pharmacother · PMID 27780133 · DOI |
Systematic review isolated-compound |
Review of the isolated compound swertiamarin, mostly from Enicostemma plants | Swertiamarin (pure compound) various Not given here Not given here |
Says swertiamarin shows anti-atherosclerotic, antidiabetic, anti-inflammatory and antioxidant effects in lab and animal work, linked to lower NF-kB expression, LDL oxidation and lipid peroxidation. The abstract names Enicostemma species, not chirata, as its source plants. Methods, limits and fundingOutcomes: Cardiac and metabolic protection (antidiabetic, anti-inflammatory, antioxidant) Limitations: Abstract only. About the isolated compound, not chirata whole plant. No human trial results in the abstract. Read: abstract |
| Malik 2019 Employing barcoding markers to authenticate selected endangered medicinal plants traded in Indian markets. Physiol Mol Biol Plants · PMID 30956417 · DOI |
Laboratory quality study laboratory |
22 herbal market samples of endangered Indian medicinal plants | Dried market herbs checked by DNA barcoding various Not given here Not given here |
Of 22 market samples checked, only one sample each of Rauvolfia serpentina and Picrorhiza kurroa was authentic. The abstract does not name chirata. Methods, limits and fundingOutcomes: Whether market samples match their label Limitations: Chirata is not named in the abstract, and a search of the open-access full text found no mention of it; so this is background on herb-market mislabelling, not a chirata finding. Funding and conflicts: Authors declared no conflict of interest. Read: abstract |
| NCBI PubChem 2026 PubChem compound records: amarogentin (CID 115149), swertiamarin (CID 442435), mangiferin (CID 5281647) pubchem.ncbi.nlm.nih.gov · Source |
Database record database |
Chemical identities | Amarogentin, swertiamarin, mangiferin not applicable Not given here Not given here |
Read 2026-10-25 by name lookup: amarogentin CID 115149 (C29H30O13); swertiamarin CID 442435 (C16H22O10); mangiferin CID 5281647 (C19H18O11). Methods, limits and fundingOutcomes: Compound identifiers and formulas Limitations: Identity check only. Read: full-text |
| Nagalekshmi 2011 Hepatoprotective activity of Andrographis paniculata and Swertia chirayita. Food Chem Toxicol · PMID 21983487 · DOI |
Animal study animal |
Swiss albino mice given paracetamol to injure the liver | Chirata (S. chirayita) extract whole plant extract (as described in the paper) Not given here Not given here |
Extracts of kalmegh (Andrographis) or chirata given by mouth at 100-200 mg/kg offered significant, dose-dependent protection against paracetamol-induced liver injury, judged by blood tests and liver tissue. Methods, limits and fundingOutcomes: Liver enzymes (GPT, GOT, ALP), bilirubin, liver tissue under the microscope, antioxidant markers Limitations: Mouse study of induced liver injury; says nothing about people. Abstract only. Read: abstract |
| Niu 2016 Amarogentin ameliorates diabetic disorders in animal models. Naunyn Schmiedebergs Arch Pharmacol · PMID 27485449 · DOI |
Animal study animal-isolated-compound |
Rats with streptozotocin-induced type 1 diabetes and rats on a fructose-rich diet (type 2 model) | Amarogentin (pure compound, a bitter compound found in chirata and other gentians) isolated compound Not given here Not given here |
Amarogentin lowered blood glucose in a dose-dependent way in diabetic rats lacking insulin, improved glucose tolerance, raised GLUT4 in muscle, lowered PEPCK in liver, and lowered HOMA-IR in the type 2 rat model. Methods, limits and fundingOutcomes: Blood glucose, glucose tolerance, GLUT4 and PEPCK protein, insulin resistance (HOMA-IR) Limitations: Pure compound in rats; not chirata itself; the abstract does not name the plant source. Read: abstract |
| Singh 2019 Ultra performance liquid chromatography coupled with principal component and cluster analysis of Swertia chirayita for adulteration check. J Pharm Biomed Anal · PMID 30412803 · DOI |
Laboratory quality study laboratory |
Five chirata ecotypes and five possible substitutes collected in the Indian Himalaya (S. bimaculata, S. chordata, S. ciliata, S. paniculata, Halenia elliptica) | Chirata whole plant samples versus look-alike substitutes whole plant Not given here Not given here |
The chemical fingerprint of the chirata samples matched each other closely (similarity above 0.925) and matched the substitutes poorly (below 0.629), so the method could detect substitution. Methods, limits and fundingOutcomes: Chemical fingerprint (swertiamarin, mangiferin, gentiopicroside, sweroside) to tell chirata from substitutes Limitations: Lab method study of a small set of samples; shows adulterants exist as possible substitutes and can be detected; does not measure how often they occur on the market. Read: abstract |
| Swati 2023 Swertia chirayita: A comprehensive review on traditional uses, phytochemistry, quality assessment and pharmacology. J Ethnopharmacol · PMID 36113678 · DOI |
Narrative review review-of-single-species |
Literature review of chirata up to March 2022 | Chirata (Swertia chirayita) whole plant, extracts and isolated compounds whole plant Not given here Not given here |
Traditional uses listed: fever, vomiting, jaundice, digestive disorders, heart disease, diabetes, malaria, scorpion bite and skin diseases. About 123 compounds isolated (xanthones, seco-iridoids, terpenoids, alkaloids, flavonoids). Reported effects in lab and animal work: anti-inflammatory, antioxidant, antitumor, hepatoprotective, antiviral, antimalarial, antibacterial. The authors say gaps remain, including safety profiles. Methods, limits and fundingOutcomes: Traditional uses, chemistry, pharmacology, toxicology, quality control Limitations: Abstract only. A narrative review: no pooled data, no quality scoring of studies, no human trial results reported in the abstract. The abstract does not say which findings are from people. Funding and conflicts: Authors declared no competing interests. Read: abstract |
| Zhou 2015 Anti-hepatitis B virus active constituents from Swertia chirayita. Fitoterapia · PMID 25447162 · DOI |
In vitro study in-vitro |
Human liver cell line carrying hepatitis B virus (HepG 2.2.15) | Compounds isolated from an ethanol extract of chirata whole plant (as described) Not given here Not given here |
Four new and 26 known compounds were isolated. Some of them lowered hepatitis B markers in infected cells in the lab (for example one compound with IC50 0.31 mM for surface antigen); eight compounds reduced viral DNA replication with IC50 values of 0.07-0.33 mM. Methods, limits and fundingOutcomes: Hepatitis B surface and e antigen release and viral DNA replication in cells Limitations: Cell-culture work only. No animal or human result. Not a treatment for hepatitis B. Read: abstract |
What we do not know yet
- No controlled human trial of chirata for any use.
- No human safety, pregnancy or interaction data.
- Products are not standardised; adulteration is a quality issue.
- Conservation status not checked on the IUCN Red List.
How new research is added
New studies are found by a saved PubMed search and placed in a review queue. A person reads each one before it is added.
Lab markers
What changed in blood or saliva tests during trials. A changed number is not the same as feeling or being healthier, and we give no "normal ranges".
Safety
What studies and official sources say about side effects, medicines and who should check first. Each point shows what kind of evidence it comes from.
Main points to know 3
- Almost no human safety data exist for chirata. No controlled trial and no human safety study of chirata was found. Reviews say there is not enough information on the safety of the plant and call for formal toxicity and clinical safety work. Traditional use over centuries and some mouse results showing no obvious toxic effects are reassuring but are not proof of safety, especially for long-term use, pregnancy or people on medicines. Authoritative guidance 7 14 4
- If you take medicines for diabetes, ask before using chirata. Chirata extracts and a pure bitter compound lowered blood sugar in animals. In theory this could add to diabetes medicines (insulin, sulfonylureas and others) and cause low blood sugar with shakiness, sweating, confusion or fainting. No human case or study was found, so this is a theoretical concern based on animal data. Do not stop or change diabetes medicines on your own. Preliminary mechanism 4 12 5
- Wild chirata is endangered, and market herbs can be substituted. Reviews say over-collection and habitat loss have put wild Himalayan chirata at risk, and that supplies are adulterated. A lab study showed look-alike Swertia species and Halenia elliptica can be told apart from chirata by chemical fingerprint, which implies they can be used as substitutes. India restricts export of wild-harvested chirata. Prefer products that name the species and say whether the plant was cultivated. Laboratory 7 3 13
Side effects 1
| Effect | How often | Severity and recovery | Evidence |
|---|---|---|---|
| Stomach upset (nausea, discomfort) Not documented in a trial. Very bitter herbs commonly upset sensitive stomachs; this is a general expectation, not a measured chirata finding. | Not established | mild Not described | Traditional reference 7 |
Liver
No human case report of liver injury from chirata was found in a short PubMed search, and LiverTox has no chirata entry that we found. This is absence of data, not proof of safety. The 'liver protection' in mice does not tell us how the herb behaves in people with liver disease or on liver-affecting medicines. Herb-labelled products can be adulterated, and any herbal product can occasionally harm the liver. 11 7
How often. No data.
Monitoring. No monitoring advice is established. Seek care for yellow skin or eyes, dark urine, pale stools or severe tiredness.
This is a safety connection. It is not evidence that Chirata supports liver health.
Medicines and supplements 3
| With | Why it matters | Importance | Evidence | What to do |
|---|---|---|---|---|
| Diabetes medicines (insulin, sulfonylureas, others) drug | Chirata extracts and amarogentin lowered blood glucose in animals; additive blood-sugar lowering is possible. | Unknown. No human interaction case or study found. | Preliminary mechanism Not enough evidence 4 12 | Tell your doctor or pharmacist before using chirata and watch for low blood sugar if you do. |
| Other blood-sugar-lowering herbs (for example bitter melon) herb | Possible additive effect if both lower blood sugar. | Theoretical only. | Pharmacological theory Not enough evidence 5 | Do not stack several blood-sugar herbs without a clinician. |
| Medicines handled by the liver (general) drug | Not studied for chirata. A 2025 gentian-family review is general and not chirata-specific. | Unknown. | Pharmacological theory Not enough evidence 1 | Tell your pharmacist you take it. |
Who should check first 5
| Situation | Advice | Evidence |
|---|---|---|
| Pregnancy and breastfeeding | No safety data were found. Avoid unless a clinician who knows your situation agrees. | Traditional reference 7 |
| Children | No safety data. Do not give to children without medical advice. | Traditional reference 7 |
| Stomach ulcer, gastritis or excess stomach acid | Bitter herbs can stimulate stomach secretions or irritate; no chirata study tested this. Ask a doctor first. | Pharmacological theory |
| Diabetes treated with medicines | Ask before use because of possible low blood sugar (theoretical). | Preliminary mechanism 4 12 |
| Planned surgery | Not studied. Tell your surgeon about any herb because of possible blood-sugar effects. | Pharmacological theory |
Overdose, product quality and regulators
Summary. The 2016 review says chirata is traced through medical history as a non-toxic, safe herb and that extracts did not cause obvious toxic effects in mice (no differences in body weight and temperature), but it also says formal toxicity and mutagenicity tests are still needed.
Animal. Mouse studies cited in the review: no obvious toxicity. Details not read beyond the review.
Human doses studied. No human studies found.
High dose or long term signals. Not studied.
Overdose response. Unknown. Seek care if you feel unwell after taking a lot.
Genotoxicity. Not tested in the sources we read; the review calls for mutagenicity tests.
Toxic plant parts. The whole plant and underground parts are used; no toxic part has been named in the sources we read.
The main concerns are look-alike substitutes and mislabelling driven by high demand and a shrinking wild supply.
Possible substitutes. A lab study compared five chirata ecotypes with five possible substitutes (four other Swertia species and Halenia elliptica) and found the chemical fingerprints clearly different, so substitution can be detected. 13
Adulteration of supplies. A 2016 review says high demand has led to unscrupulous collection and adulteration of supplies. 7
Mislabelling of endangered herbs in markets (general). A DNA study of 22 Indian market herb samples found only two authentic samples (not chirata). Chirata was not named in what we read. 9
| Body | Action | Date |
|---|---|---|
| Government of India (export rule) (India) | Since 2004, export of wild-harvested chirata, its parts and extracts is prohibited, except for formulations. source | 2004 |
When to get medical help
- Shaking, sweating, confusion or fainting after using chirata with diabetes medicines (possible low blood sugar).
- Yellow skin or eyes, dark urine or severe tiredness after a herbal product.
- Fever that lasts more than a day or two, or any fever after travel to a malaria area: seek medical care, do not treat malaria with herbs.
Stop the supplement and contact a clinician or emergency service. In the US, Poison Control is 1-800-222-1222.
General information only, not medical advice. Ask a clinician or pharmacist before use, especially with medicines, in pregnancy or with a health condition. See the Natural Remedy Safety guide.
Frequently asked questions
What is chirata?
Does chirata work for diabetes?
Can chirata cause low blood sugar with diabetes medicines?
Is chirata good for the liver?
Does chirata help digestion or appetite?
Can chirata treat malaria?
Is chirata safe in pregnancy or while breastfeeding?
We found no safety data, so it is best avoided unless a clinician who knows your situation agrees.
Is chirata safe for the liver?
Is chirata endangered?
How do I avoid fake or substituted chirata?
Explore by health goal
Cellular ProtectionBlood Sugar BalanceMetabolic HealthLiver SupportDigestive SupportGut HealthInflammation BalanceImmune Support
Editorial transparency
- Written by
- AlternativeMed editorial team. Research compiled with AI assistance, then checked against PubMed records.
- Medical review
- None. This page has not been reviewed by a physician or pharmacist.
- First published
- 2026-10-25
- Last substantive update
- 2026-10-25
- How we research
- We read our existing herb summary, then searched PubMed, read the abstract of each PubMed record cited, and checked names in GBIF and PubChem. Items marked summary-only or not verified were not read further.
- How we rate evidence
- See "How we rate evidence" in the Evidence tab.
- Independence
- No product is promoted on this page. No affiliate links are shown.
Sources 15
Each source was opened and checked. Where we read only the abstract, it says so. The small numbers in the text point here.
- Andryszkiewicz W, Chmielewska M, Ciecierska J, Lenkiewicz P, Marciniak W, Raczycka W, Wojno A, Kulbacka J, Niewiński P, Bieżuńska-Kusiak K. Gentianaceae Family-Derived Bioactive Compounds-Therapeutic Values and Supporting Role in Inflammation and Detoxification.. Nutrients. 2025. PMID 40871648. DOI 10.3390/nu17162619. (abstract)
- Bhat GP, Surolia N. In vitro antimalarial activity of extracts of three plants used in the traditional medicine of India.. Am J Trop Med Hyg. 2001. PMID 11693874. DOI 10.4269/ajtmh.2001.65.304. (abstract)
- Cunningham AB, Brinckmann JA, Schippmann U, Pyakurel D. Production from both wild harvest and cultivation: The cross-border Swertia chirayita (Gentianaceae) trade.. J Ethnopharmacol. 2018. PMID 29960022. DOI 10.1016/j.jep.2018.06.033. (abstract)
- Dey P, Singh J, Suluvoy JK, Dilip KJ, Nayak J. Utilization of Swertia chirayita Plant Extracts for Management of Diabetes and Associated Disorders: Present Status, Future Prospects and Limitations.. Nat Prod Bioprospect. 2020. PMID 33118125. DOI 10.1007/s13659-020-00277-7. (abstract)
- Dinić S, Vidaković M, Arambašić Jovanović J, Uskoković A, Grdović N, Đorđević M, Rajić J, Mihailović M. Therapeutic Potential of Gentianaceae Family Plants in the Treatment of Diabetes and Its Complications.. Biomedicines. 2025. PMID 41301913. DOI 10.3390/biomedicines13112822. (abstract)
- GBIF Secretariat. GBIF species match: Swertia chirayita and Swertia chirata. api.gbif.org. 2026. (full-text)
- Kumar V, Van Staden J. A Review of Swertia chirayita (Gentianaceae) as a Traditional Medicinal Plant.. Front Pharmacol. 2016. PMID 26793105. DOI 10.3389/fphar.2015.00308. (full-text (partial))
- Leong XY, Thanikachalam PV, Pandey M, Ramamurthy S. A systematic review of the protective role of swertiamarin in cardiac and metabolic diseases.. Biomed Pharmacother. 2016. PMID 27780133. DOI 10.1016/j.biopha.2016.10.044. (abstract)
- Malik S, Priya A, Babbar SB. Employing barcoding markers to authenticate selected endangered medicinal plants traded in Indian markets.. Physiol Mol Biol Plants. 2019. PMID 30956417. DOI 10.1007/s12298-018-0610-8. (abstract)
- NCBI PubChem. PubChem compound records: amarogentin (CID 115149), swertiamarin (CID 442435), mangiferin (CID 5281647). pubchem.ncbi.nlm.nih.gov. 2026. (full-text)
- Nagalekshmi R, Menon A, Chandrasekharan DK, Nair CK. Hepatoprotective activity of Andrographis paniculata and Swertia chirayita.. Food Chem Toxicol. 2011. PMID 21983487. DOI 10.1016/j.fct.2011.09.026. (abstract)
- Niu HS, Chao PC, Ku PM, Niu CS, Lee KS, Cheng JT. Amarogentin ameliorates diabetic disorders in animal models.. Naunyn Schmiedebergs Arch Pharmacol. 2016. PMID 27485449. DOI 10.1007/s00210-016-1283-x. (abstract)
- Singh M, Mohan R, Mishra S, Goyal N, Shanker K, Gupta N, Kumar B. Ultra performance liquid chromatography coupled with principal component and cluster analysis of Swertia chirayita for adulteration check.. J Pharm Biomed Anal. 2019. PMID 30412803. DOI 10.1016/j.jpba.2018.10.054. (abstract)
- Swati K, Bhatt V, Sendri N, Bhatt P, Bhandari P. Swertia chirayita: A comprehensive review on traditional uses, phytochemistry, quality assessment and pharmacology.. J Ethnopharmacol. 2023. PMID 36113678. DOI 10.1016/j.jep.2022.115714. (abstract)
- Zhou NJ, Geng CA, Huang XY, Ma YB, Zhang XM, Wang JL, Chen JJ. Anti-hepatitis B virus active constituents from Swertia chirayita.. Fitoterapia. 2015. PMID 25447162. DOI 10.1016/j.fitote.2014.11.011. (abstract)